JPS5838209A - Tannin-containing composition for skin for external application - Google Patents

Tannin-containing composition for skin for external application

Info

Publication number
JPS5838209A
JPS5838209A JP56135771A JP13577181A JPS5838209A JP S5838209 A JPS5838209 A JP S5838209A JP 56135771 A JP56135771 A JP 56135771A JP 13577181 A JP13577181 A JP 13577181A JP S5838209 A JPS5838209 A JP S5838209A
Authority
JP
Japan
Prior art keywords
tannin
skin
extract
tannins
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56135771A
Other languages
Japanese (ja)
Inventor
Takuo Okuda
奥田拓男
Seiichi Iida
飯田誠一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunstar Inc
Original Assignee
Sunstar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunstar Inc filed Critical Sunstar Inc
Priority to JP56135771A priority Critical patent/JPS5838209A/en
Publication of JPS5838209A publication Critical patent/JPS5838209A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Abstract

PURPOSE:The titled composition that contains a tannin having a specific group such as hexahydroxydiphenoyl as an active ingredient, thus developing good effect of preventing and treating dermatitis by the strong antiplasmic action of the tannin. CONSTITUTION:A tannin containing groups selected from hexahydroxydiphenoyl and dehydrohexahydroxydiphenoyl, preferably ellagitannin or elm tannin, is added as an active ingredient, preferably by 0.05-5wt% based on the total amount of the composition, to give the objective composition for external application for preventing skin inflammation caused by stimulation such as ultraviolet rays, curing or restoring inflamed skins such as rough skin, sun burn, heat burn, or eczema with no problems on irritation of skins and discomfort on application.

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はタンニン配合皮膚外用剤組成物、さらに詳しく
は、紫外線などの刺激による皮膚の炎症を防ぎ、壕だ、
肌荒れ、日やけ、熱傷、湿疹などの炎症の生じた皮膚を
正常にし、治療するタンニン配合の皮膚外用剤組成物に
関する。 このような皮膚外用剤組成物として、従来から種々のも
のが知られておシ、例えば1日やけどめニハハラアミノ
安息香酸−アントラニル酸、サリチ/l/酸などの紫外
線吸収剤、タルク、亜鉛華などの光線散乱剤を配合した
ものが用いられている。 しかし−これらは皮膚刺激性、安定性、持続性。 皮膚感作性などの点で問題がある。また1日やけ。 熱傷、湿疹などの炎症にはカラミンなどの収斂斉一ビタ
ミンCなどのビタミン剤、スルファジアジンなどの消毒
殺菌剤、ジフェンヒドラミンなどの抗ヒスタミン剤、バ
シトラシンなどの抗生物質、フルオンノロンアセトナイ
ドなどの副腎皮質ホルモン剤、アズレンなどの消炎剤な
どを適宜配合した組成物が整肌と炎症の治療に用いられ
ているが、−゛これらの薬効剤は他の配合成分との関係
から効果を発揮できなかったシ、局所適用における安全
性、有効性の点で必ずしも満足しえない。 一般に一皮膚炎症については、生体内の線溶系に閏年す
る蛋白分解酵素であるプラスミンとの関係がよく知られ
ておシ、日やけ、熱傷、湿疹、接触性皮膚炎、エリテマ
トーデスなどの皮膚疾患においてプラスミン活性が上昇
し−その一原因になっていると考えられている。 本発明者らは、前記のような問題や欠点を解消した皮膚
炎症の予防、治療効果を有する皮膚外用剤組成物を得る
べく、プラスミン活性の抑制の観点から研究を重ねる間
に、ある種の生薬やその他の植物から得られる特定のタ
ンニンがきわめてすぐれた抗プラスミン活性を有し、皮
膚外用剤組成物に配合するのに適した薬効剤であること
を見出した。 タンニンは加水分解性タンニンと縮合型タンニンに分け
られ、糖または環状多価アルコールにガロイル基または
その誘導体が結合したものと、カテキン、エビカテキン
のようなフラバン−3−オールなどの縮合体が構造の基
本になっているものと区別される。前者はさらにガロイ
ル基のみが結合しているガロタンニンと−へキサヒドロ
キシジフェノイル、デヒドロヘキサヒドロキシジフェノ
イルなどやその類縁化合物が結合しているタンニンに区
別できる。一般に、タンニンは蛋白吸着作用を有し、そ
れにより止血効果を発揮するものがあると考えられてい
るが、タンニンを明確に分類し、特定のタンニンの作用
、効果がいかなるものであるかを解明した例はあまり見
当らない。 本発明者らは、蛋白質分解酵素抑制作用を示す生薬、゛
植物にタンニン含量の多いものがみられることに着目し
、それらのタンニンの種類および含量と抗プラスミン活
性の関係について検討した。 その結果、タンニン含量の多い生薬、植物が強い抗プラ
スミン活性を示す傾向にあるが、タンニン含量と抗プラ
スミン活性の強弱とは必ずしも一致せず、種々のタンニ
ンのうチ、ヘキサヒドロキンジフェノイル基やデヒドロ
ヘキサヒドロキシジフェノイル基を有する。利子から得
られるテルヶビン(terchebin )、ケグリン
酸(cheblinic acid )。 ケフラジ酸(chebulagic acid ) −
7カメガシワから得られる一?ロッS/7酸(mall
otusinic acid ) オよびザクロにも含
まれるプニカラジン(punicalagin )、オ
オパヤシャプシから得られるアルヌシイン(alnus
iin ) 、ゲンノショウコやアカメガシワから得ら
れるゲラニイン(geraniin )のようなエラジ
タンニンおよび地楡から得られる地楡タンニンがその蛋
白吸着作用(タンニン定量値)と比較してことに強い抗
プラスミン活性を示し。 それにより、すぐれた皮膚炎症の予防、治療効果を発揮
することが判明した。 本発明はかかる知見に基いて完成されたものであって、
有効成分として、ヘキサヒドロキンジフェノイル基およ
びデヒドロヘキサヒドロキシジフェノイル基からなる群
から選ばれる基を含むタンニンの1種または2種以上を
配合したことを特徴とする皮膚外用剤組成物を提供する
ものであり、本発明の皮膚外用剤組成物は配合したタン
ニンの作用により、すぐれた整肌作用、抗炎症作用を発
揮し一皮膚刺激や使用感の点でも問題もなく、日やけ、
肌荒れを予防し1日やけ、肌荒れ、熱傷。 湿疹などの炎症の生じた皮膚を正常にし、治療するに際
してきわめて有用である。 つぎに、各種の生薬由来のタンニンの抗プラスミン活性
を比較した結果を示す。各タンニンの抗プラスミン活性
は、各タンニンのヘモグロビン吸着強度(タンニン定量
値)に対するその抗プラスミン活性の比をつぎのとおり
測定し1局方タンニン酸を1として比較した。なお、同
様に原料生薬粗抽出物の抗プラスミン活性も比較した。 (1)試料、の調製 (1)原料生薬、植物:テルケビン、ケブリン酸。 ケプラジ酸用に利子、マロツシン酸、プニカラジン用に
アカメガシワ乾燥葉、アルヌシイン用にオオハヤシャプ
シ果実、ゲラニイン用にゲンノショウコおよびモクマオ
ウ乾燥葉を用いた。また、地楡タンニン用に地楡、何首
烏タンニン用に何首烏、大苗タンニン用に稚苗および信
州大賀を用いた。 さらに牡丹皮、荀薬、麻黄も試験した。 (11)粗抽出物の調製:各原料生薬植物10gを水−
アセトン(1:1)混液に浸し、ミキサーで均質化しな
がら室温で15分間抽出し、濾過した。 この操作を3回くり返し、炉液を合し、濃縮乾固して粗
抽出物を調製した。 011)エツジタンニンの調製:(1)で得られた粗抽
出物を水に溶解し、エチルエーテルで洗浄後、酢酸エチ
ルで10回抽出し、全抽出液を40°Cで減圧下、濃縮
乾固した。残渣を、n−ブタノール−酢酸−水(4:1
:5)混液を用いて液滴向流分配クロマトグラフィーに
付し、上昇法で展開して各両分を分取した。各両分につ
き、後記の方法に従ってタンニン定量値を測定し、高い
定量値を示した画分を40°Cで減圧下、濃縮乾固し、
所望のエツジタンニンを得た。なお、得られた各エツジ
タンニンはIR,HMRおよびHPLCで同定した。 怜縮合型タンニンの調製;(1)で得られた粗抽出物を
(曲におけると同様に処理して酢酸エチル抽出物を得た
。こわをセファデックスLH−20上でクロマトグラフ
ィーに付し、エタノールで低分子ポリフェノールを溶出
させた。ついで、エタノール−水混液で溶出をつづけ、
水の割合を徐々に増加させ、30%に達したところで、
さらにアセトンを加え、その割合を徐々に増加させ、エ
タノールを徐々に減らしてエタノール−水−アセトン(
8:8:4)になるまで溶出をつづけた。分取した各両
分のタンニン定量値を測定し、高い定量値を示した両分
を濃縮乾固し、所望の縮合型タンニンを得た。 (2)抗プラスミン活性の測定 各試料を0.15M食塩加0.01Mリン酸緩衝液(p
H7,8)に分散、溶解して種々の濃度の試料溶液を調
製する。ウオレンらCWallen et al。 Haemostasis 4. 110 (1975)
 〕の方法に準じ、アガロ−y、 100”fを0.1
5M食塩加0.01Mリン酸緩衝液(pH7,8)10
rnlに加熱、溶解後、40°Cに冷却する。これにプ
ラスミノーゲン除去フィブリノーゲン(第一化学薬品)
20Wを溶解し、トロンビン溶液
The present invention provides a tannin-containing skin external preparation composition, more specifically, it prevents skin inflammation caused by stimulation such as ultraviolet rays,
This invention relates to an external skin preparation composition containing tannins that normalizes and treats irritated skin such as rough skin, sunburn, burns, and eczema. Various kinds of skin external preparation compositions have been known for a long time, such as ultraviolet absorbers such as 1-day burn nihahara aminobenzoic acid-anthranilic acid, salicylic acid, talc, zinc white, etc. A compound containing a light scattering agent is used. However – they are skin irritating, stable and persistent. There are problems with skin sensitization. Another day burnt. For inflammation such as burns and eczema, use astringent vitamins such as calamine, vitamins such as vitamin C, disinfectants such as sulfadiazine, antihistamines such as diphenhydramine, antibiotics such as bacitracin, corticosteroids such as fluoronolone acetonide, Compositions containing appropriate anti-inflammatory agents such as azulene are used to condition the skin and treat inflammation. It is not always satisfactory in terms of safety and effectiveness in application. In general, skin inflammation is well known to be related to plasmin, a proteolytic enzyme that leaps into the fibrinolytic system in the body, and is associated with skin diseases such as acne, sunburn, burns, eczema, contact dermatitis, and lupus erythematosus. Increased plasmin activity is believed to be one of the causes. In order to obtain a skin external preparation composition that eliminates the above-mentioned problems and disadvantages and has preventive and therapeutic effects on skin inflammation, the present inventors have conducted research from the viewpoint of suppressing plasmin activity, and have discovered certain We have discovered that certain tannins obtained from crude drugs and other plants have extremely excellent antiplasmin activity and are medicinal agents suitable for inclusion in external skin preparation compositions. Tannins are divided into hydrolyzable tannins and condensed tannins, and those with a galloyl group or its derivatives bound to sugar or cyclic polyhydric alcohol, and condensates of flavan-3-ols such as catechin and shrimp catechin have a structure. It is distinguished from what is the basis of. The former can be further divided into gallotannins, which have only galloyl groups bonded to them, and tannins, which have -hexahydroxydiphenoyl, dehydrohexahydroxydiphenoyl, etc., or their analogues bonded to them. It is generally believed that tannins have a protein-adsorbing effect, thereby exerting a hemostatic effect, but it is necessary to clearly classify tannins and elucidate the functions and effects of specific tannins. I can't find many examples of this. The present inventors have focused on the fact that there are herbal medicines that exhibit proteolytic enzyme inhibitory effects, such as those found in plants that have a high tannin content, and have investigated the relationship between the type and content of these tannins and their anti-plasmin activity. As a result, herbal medicines and plants with high tannin content tend to exhibit strong anti-plasmin activity, but the tannin content and the strength of anti-plasmin activity do not necessarily match, and various tannin cavities and hexahydroquine diphenoyl groups It has a dehydrohexahydroxydiphenoyl group. Terchebin, cheblinic acid obtained from interest. Chebulagic acid -
What can you get from 7 turtle wrinkles? Ross S/7 acid (mall
otusinic acid) punicalagin, which is also found in otusinic acid and pomegranate;
iin), ellagitannins such as geraniin obtained from gennoshoko and geraniin, and geraniin tannins obtained from elms show particularly strong antiplasmin activity compared to their protein adsorption activity (tannin quantitative value). As a result, it has been found to have excellent preventive and therapeutic effects on skin inflammation. The present invention was completed based on such knowledge, and
Provided is a composition for external use on the skin, which contains as an active ingredient one or more tannins containing a group selected from the group consisting of hexahydroquine diphenoyl group and dehydrohexahydroxydiphenoyl group. The skin external preparation composition of the present invention exhibits excellent skin conditioning and anti-inflammatory effects due to the action of the blended tannins, and has no problems in terms of skin irritation or feeling of use, and is effective against sunburn,
Prevents rough skin, sunburn, rough skin, and burns. It is extremely useful in normalizing and treating inflamed skin such as eczema. Next, we will show the results of comparing the anti-plasmin activities of tannins derived from various herbal medicines. The anti-plasmin activity of each tannin was determined by measuring the ratio of the anti-plasmin activity to the hemoglobin adsorption strength (quantitative value of tannin) of each tannin as follows, and comparing it with one pharmacopoeial tannic acid as 1. In addition, the anti-plasmin activity of raw crude drug crude extracts was also compared in the same manner. (1) Preparation of samples (1) Raw materials, crude drugs, plants: terkevin, chebric acid. Dry leaves of Akamega sinensis were used for kepradiic acid, malotsic acid, and punicalagin, dried leaves of Acanthus japonica were used for alnusiin, and dry leaves of Gennoshoko and Casuarina were used for geraniin. In addition, Jiyu was used for Jiyu tannin, Nakhu Karasu was used for Hekukarasu tannin, and Seinae and Shinshu Ohga were used for Dainae tannin. Additionally, Peony bark, Xun medicine, and Ephedra were also tested. (11) Preparation of crude extract: 10g of each raw medicinal plant in water.
It was soaked in an acetone (1:1) mixture, extracted for 15 minutes at room temperature while homogenizing with a mixer, and filtered. This operation was repeated three times, and the furnace liquids were combined and concentrated to dryness to prepare a crude extract. 011) Preparation of edzitannin: The crude extract obtained in (1) was dissolved in water, washed with ethyl ether, extracted 10 times with ethyl acetate, and the entire extract was concentrated and dried at 40°C under reduced pressure. Hardened. The residue was dissolved in n-butanol-acetic acid-water (4:1).
:5) The mixed solution was subjected to droplet countercurrent partition chromatography and developed using an ascending method to separate both fractions. For each fraction, the tannin quantitative value was measured according to the method described below, and the fraction that showed a high quantitative value was concentrated to dryness at 40°C under reduced pressure.
The desired ethugitannin was obtained. In addition, each obtained edgitannin was identified by IR, HMR, and HPLC. Preparation of condensed tannins: The crude extract obtained in (1) was treated in the same manner as in the previous section to obtain an ethyl acetate extract.The residue was chromatographed on Sephadex LH-20, Low-molecular-weight polyphenols were eluted with ethanol. Next, elution was continued with an ethanol-water mixture.
Gradually increase the proportion of water until it reaches 30%.
Furthermore, add acetone, gradually increase the proportion, and gradually reduce ethanol to form ethanol-water-acetone (
Elution was continued until the ratio was 8:8:4). The tannin quantitative value of each separated fraction was measured, and both fractions showing high quantitative values were concentrated to dryness to obtain the desired condensed tannin. (2) Measurement of antiplasmin activity Each sample was dissolved in 0.01M phosphate buffer (p
H7, 8) to prepare sample solutions of various concentrations. Wallen et al. Haemostasis 4. 110 (1975)
], agaro-y, 100”f was adjusted to 0.1
0.01M phosphate buffer with 5M sodium chloride (pH 7,8) 10
After heating and dissolving in rnl, cool to 40°C. This includes plasminogen removal fibrinogen (Daiichi Chemical)
Dissolve 20W and thrombin solution

【100単位/−1持
田製薬30.1it滴下した後、シャーレ(径91:W
)に注ぐ。室温で冷却後、中心に直径6Hの穴をあけて
プラスミノーゲン除去フィブリンプレートを調製する。 アムプ〃スら(Ambrus et al。 Pediatrics、  82. 10(1968)
”)の方法に従い、前記で調製した種々の濃度の試料溶
液0.1−にプラスミン溶液(0,4単位/1n!、シ
グマ社)0.1−を加え、30分後、プラスミノーゲン
除去フィブリンプレートにあけた穴に、各々、20μl
ずつ注入する。37°Cで20時間放置後、溶解面積を
測定する。試料無添加の場合の溶解面積と比較し、プラ
スミン活性の50%阻ビ濃度(ID50)を算出し、次
式に従うて局方タンニン酸のID50との比(RIp 
)を求める。 (3)タンニン定量値 集用ら〔薬学雑誌、96,1143(1976)〕の方
法に従って、各試料の吸着ヘモグロビン量をつぎのとお
り測定する。 各試料を0.2 M ’Jン酸緩衝液【田6.O】に分
散。 溶解して種々の濃度の試料溶液を調製する。試料mH2
mt、ヘモグロビン溶液
After dropping 100 units/-1 Mochida Pharmaceutical 30.1 it, place it in a petri dish (diameter 91: W
). After cooling at room temperature, a hole with a diameter of 6H is made in the center to prepare a plasminogen-depleted fibrin plate. Ambrus et al. Pediatrics, 82. 10 (1968)
”), add 0.1- of plasmin solution (0.4 units/1n!, Sigma) to 0.1- of sample solutions of various concentrations prepared above, and after 30 minutes, remove plasminogen. 20μl each into the holes made in the fibrin plate.
Inject one by one. After standing at 37°C for 20 hours, the area of dissolution is measured. The 50% inhibitory concentration (ID50) of plasmin activity was calculated by comparing with the dissolution area when no sample was added, and the ratio to the ID50 of pharmacopoeial tannic acid (RIp) was calculated according to the following formula.
). (3) The amount of adsorbed hemoglobin in each sample is measured as follows, according to the method of Tannin Quantitative Value Collection, et al. [Pharmacy Journal, 96, 1143 (1976)]. Add each sample to 0.2 M 'J acid buffer [6. Dispersed in O]. Prepare sample solutions of various concentrations by dissolving. Sample mH2
mt, hemoglobin solution

【ヒト新鮮血に水を加え、溶血
させ、 0D57B = 2.5としたもの】2−およ
び0.2Mリン酸緩#液(−pH6,0) 1−を混合
。 攪拌し、1時間放置する。ついで、1200Orp、m
、で10盆間遠心分離し、上澄液の578nmにおける
吸光度を測定し、ヘモグロビン無添加の場合の吸光度と
の差から吸着ヘモグロビン量を求める。試料無添加の場
合のヘモグロビン量と比較して50%吸着濃度(ID5
0)を算出し、次式に従って局方タンニン酸のED 5
0  との比(RA )−i求める。 各試料のID50 結果をつぎの第1表に示す。 第1表 第1表
[Fresh human blood was hemolyzed by adding water to give 0D57B = 2.5] 2- and 0.2M phosphoric acid solution (-pH 6,0) 1- were mixed. Stir and let stand for 1 hour. Then, 1200 Orp, m
The supernatant was centrifuged for 10 trays, the absorbance of the supernatant was measured at 578 nm, and the amount of adsorbed hemoglobin was determined from the difference from the absorbance when no hemoglobin was added. 50% adsorption concentration (ID5) compared to the amount of hemoglobin when no sample is added
0) and calculate the ED 5 of pharmacopoeial tannic acid according to the following formula:
Find the ratio (RA)-i with respect to 0. The ID50 results for each sample are shown in Table 1 below. Table 1 Table 1

【つづき】[continued]

第1表に示すごとく、ヘキサヒドロキシジフェノイル基
やデヒドロヘキサヒドロキシジフェノイル基を有するエ
ツジタンニンおよび地楡タンニンが局方タンニン酸と同
等またはそれ以上の強い抗プラスミン活性を有する。 かくして1本発明の皮膚外用剤組成物にはヘキサヒドロ
キシジフェノイル基およびデヒドロヘキサヒドロキシジ
フェノイル基から選ばれる基を有するタンニン、代表的
には、エツジタンニン、地楡タンニンを有効成分として
配合する。 用いるエツジタンニンとしては、前記した利子。 アカメガシワ、オオバヤシャプン、ゲンノンヨウコのよ
うな生薬から抽出されるテρケビン、ケプリン酸、ケプ
ラジ酸、マロツンン酸、プニカラジン、アルヌシイン、
ゲラニインの他、ザクロのグラナチン(granati
n ) AおよびB−プニカリン(punicalin
 )、丁字、サン7ユユのテリマグランジy (tel
limagrandin ) lおよびI、イソfNl
rピン(1soterchebin ) 、 モクマオ
ウのカジュアリニン(casuarinin ) 、カ
ジュアリクチン(casuarictin)、ヌトリク
チ= 7 (5LricLinin )およびユーカリ
にも含まれるベドンクラジン(pedunculagi
n )%ゲンノショウコのデヒドロゲラニイン(deh
ydro−granin )、フーロシン(furos
in )などが挙げられる。 本発明で用いるエツジタンニン、地楡タンニンの抽出法
は特に限定するものではないが、通常。 まず、原料生薬、植物を30〜70%アセトン水溶液ま
たは30〜100%アルコール水溶液で充分抽出する。 これらの抽出溶媒は原料の乾燥程度に応じて適宜選択で
きるが一一般に、生薬ではアセトン−水(1:11混液
が好ましい。抽出溶媒量は原料に対して2〜10倍の割
合で用い、室温〜60°C,15分〜1時間程度の抽出
を3回くυ返せば充分である。ことに、ミキサーで均質
化しながら室温で充分抽出をすることがタンニンの分解
を防ぎ、収率全向上させる上で好ましい。 ついで、全抽出液を60°C以下で濃縮し、乾固すれば
タンニンを含む粗抽出物が得られる。 この粗抽出物を水に溶解させるか、先に得られた抽出液
からアセトン、アルコ−/l’を除去した液を約同量の
エチルエーテルで洗浄する。この溶液を酢酸エチルでよ
く抽出する。通常、溶液の半量以下の酢酸エチpで3〜
20回抽出する。全抽出液を合し、60’C以下で濃縮
乾固し、タンニンを多量に含む精製抽出物を得る。なお
、この抽出の際、水溶液のpHを適当に調節することに
より所望のタンニンを多量に含む抽出物を得ることがで
きる。例えば、声6でテルケピン%声5でゲラニイン、
pH2でケプリン酸あるいはマロツシン酸が主として得
られる。 つぎに、この抽出物をクロマトグラフィーに付し、タン
ニン画分を分離する。かかる分離法も特に限定するもの
ではないが、エツジタンニンでは向流分配クロマトグラ
フィー、地楡タンニンテハゲ/I/p過法が好ましい。 例えば−エツジタンニンでは、酢酸エチル−〇−フロパ
ノール−水系またはn−ブタノール−酢酸−水系溶媒の
下層に前記抽出物を溶解し、上層を移動層として上昇法
で展開するか、メタノール−水系溶媒を用いヤ下降法で
展開して所望のエツジタンニンを分画する。 地楡タンニンでは、セファデックスLH,20を用い、
エタノールで溶出して低分子ポリフェノールを除去した
後、50〜70%アセトン水溶液で溶出して総タンニン
画分を得る。この画分を濃縮シ、再度、セファデックス
LH−20上でクロマトグラフィーに付し、エタノール
−水−アセトン混液で溶出する。エタノールとアセトン
の比率を変化させることにより、所望の分子量を有する
地楡タンニンを得ることができる。 各溶出液とも、60°C以下、好ましくは40°Cで濃
縮乾固して各エツジタンニン、地検タンニンを得る。 得られたタンニンは各々、単独で、あるいは。 2種以上を併用して用いることができる。なお、あらか
じめ2種以上の原料生薬、植物を混合し。 それからタンニンを抽出してもよい。また、これらのタ
ンニンは前記の粗抽出物または精製抽出物の形で用いて
もよい。 本発明の皮膚外用剤組成物におけるこれらタンニンの配
合量は実際の剤形等に応じて適宜選択できるが、一般に
1組成物全量に対して0.05〜5%(重量%、以下同
じ)(粗抽出物の場合は0.1〜lO%程度)の割合で
配合することにより充分に所望の効果が発揮される。 本発明の皮膚外用剤組成物は実際の用途に応じ、常法に
従ってクリーム、乳液、化粧水、クレンジング、パック
−石鹸などの化粧料、軟膏剤、パスタ剤、ローション剤
、チンキ剤、リニメント剤。 ゼリー剤、エアゾル剤などの外用医薬品のような剤形に
することができる。他の配合成分は通常用いられるもの
いずれでもよく、さらに他の薬効剤を併用してもよい。 つぎに参考例および実施例を挙げて本発明をさらに詳し
く説明する。 参考例1 市販ノ詞子(Termimlla chebura R
etzius )の果実粉末1 kqをメタノ−IV2
!中、室温で1時間攪拌後、抽出液を炉取する。この操
作を3回くり返し、全抽出液を60°C以下で減圧下に
濃縮乾固して粗抽出物を得る。 この抽出物を1jの水に溶解し一0°Cに冷却し、攪拌
しながらIN水酸化ナトリウム水溶液を加えて田6.0
に調整する。酢酸エチルで4日間減圧下に連続抽出し、
抽出液から減圧下、40°C以下で溶媒を留去する。残
渣を水0.61に溶解し、エチルエーテルで12時間連
続抽出し、ついで−エーテルを除去後、水層を減圧下、
60°C以下で濃縮乾固し、タンニンを多量に含有する
調子精製抽出物70gを得る。 この抽出物10gを液滴向流分配クロマトグラフィーに
付し、酢酸エチ/I/−n−プロパノ−〜−水(4:2
ニア 1混液で、上昇法により展開し。 0.4〜0.71の画分を捕集する。減圧下%40°C
以下で濃縮し、濃縮物をエタノールにf4解し、水を加
え、析出した沈澱を炉取して淡褐色粉末状のテルケビン
0.1gを得る。 参考例2 ケンノショウコ末乾燥葉1 kgをメタノール−水(1
:1)混液5!中、1時間ミキサーで均質化し、抽出液
を戸数する。この操作を3回くυ返し。 全抽出液を60°C以下で、濃縮乾固し、粗抽出物25
0gを得る。 この抽出物200gを水1/に溶解し、これにエチルエ
ーテN11を加えてよく振とうし、エチルエーテル層を
除去する。この操作を3回くシ返した後、残った水層に
酢酸エチtL10.81を加え、よく振とうして抽出す
る。この操作を10回くり返した後、抽出液を合し、4
0°C以下で減圧濃縮乾固し、精製抽出物5.5gを得
る。 この抽出物3gを液滴向流分配クロマトグラフィーに付
し、クロロホルム−メタノール−水(45:50:2.
1)混液を用い、下降法により展開する。0.31〜0
.41の画分を捕集し、減圧下。 40°Cで濃縮し、水より析出した沈澱を併収し。 黄色粉末状のゲラニイン0.2gをiる。 参考例3 アカメガシワの新鮮葉1 kgに水−アセトン
As shown in Table 1, edzi tannins and eligi tannins having a hexahydroxydiphenoyl group or a dehydrohexahydroxydiphenoyl group have strong antiplasmin activity equal to or greater than that of pharmaceutical tannic acid. Thus, 1. The skin external preparation composition of the present invention contains tannins having a group selected from hexahydroxydiphenoyl group and dehydrohexahydroxydiphenoyl group, typically edzi tannin and jiyue tannin as an active ingredient. do. As the ethugitannin used, the above-mentioned interest is used. Extracted from herbal medicines such as Akamegashiwa, Obayashapun, and Gennon Yoko, teρkevin, keprinic acid, kepraziic acid, malotunnic acid, punicalazin, alnuciin,
In addition to geraniin, pomegranate granatin
n) A and B-punicalin
), Choji, San7 Yuyu's Terima Grunge y (tel
limagrandin) l and I, isofNl
soterchebin, casuarinin of Casuarina, casualictin, 5LricLinin, and pedunculagin, which is also found in eucalyptus.
n)% Gennoshoko dehydrogeraniin (deh
hydro-granin), furosin (furosin),
in ), etc. The method for extracting the natural tannin and the natural tannin used in the present invention is not particularly limited, but is generally used. First, raw herbal medicines and plants are sufficiently extracted with a 30-70% acetone aqueous solution or a 30-100% alcohol aqueous solution. These extraction solvents can be selected as appropriate depending on the degree of dryness of the raw materials, but in general, for crude drugs, acetone-water (1:11 mixture) is preferred.The amount of extraction solvent is used in a ratio of 2 to 10 times the raw materials, and Extraction at ~60°C for 15 minutes to 1 hour, repeated 3 times, is sufficient.In particular, thorough extraction at room temperature while homogenizing with a mixer prevents tannin decomposition and improves the overall yield. This is preferable for the purpose of increasing the concentration of tannins.Then, the entire extract is concentrated at 60°C or below and dried to obtain a crude extract containing tannins.This crude extract can be dissolved in water, or the previously obtained extract can be dissolved in water. The solution from which acetone and alcohol/l' have been removed is washed with about the same amount of ethyl ether.This solution is thoroughly extracted with ethyl acetate.Usually, 3 to 30% of the solution is extracted with ethyl acetate, which is less than half the volume of the solution.
Extract 20 times. All the extracts are combined and concentrated to dryness below 60'C to obtain a purified extract containing a large amount of tannins. Note that during this extraction, an extract containing a large amount of desired tannins can be obtained by appropriately adjusting the pH of the aqueous solution. For example, Terkepin% with voice 6, Geraniin with voice 5,
At pH 2, capric acid or malotsic acid is mainly obtained. Next, this extract is subjected to chromatography to separate the tannin fraction. Although such separation method is not particularly limited, countercurrent partition chromatography and natural tannin separation/I/p filtration method are preferable for edge tannin. For example, for edzitannin, the extract is dissolved in the lower layer of an ethyl acetate-〇-furopanol-water system or n-butanol-acetic acid-water system solvent, and the upper layer is used as a mobile phase and developed by the ascending method, or a methanol-water system solvent is used. The desired edgitannins are fractionated by development using a descending method. Sephadex LH, 20 is used for eldest tannin,
After removing low-molecular polyphenols by elution with ethanol, the total tannin fraction is obtained by elution with a 50-70% acetone aqueous solution. This fraction was concentrated and chromatographed again on Sephadex LH-20, eluting with an ethanol-water-acetone mixture. By varying the ratio of ethanol and acetone, it is possible to obtain elm tannin with a desired molecular weight. Each eluate is concentrated to dryness at 60°C or below, preferably at 40°C to obtain each of the original tannins and the district inspection tannins. The resulting tannins may be used individually or separately. Two or more types can be used in combination. In addition, two or more kinds of raw materials, herbal medicines, and plants are mixed in advance. The tannins may then be extracted. Moreover, these tannins may be used in the form of the above-mentioned crude extract or purified extract. The blending amount of these tannins in the skin external preparation composition of the present invention can be appropriately selected depending on the actual dosage form, etc., but in general, it is 0.05 to 5% (wt%, same hereinafter) based on the total amount of one composition ( In the case of a crude extract, the desired effect can be sufficiently exhibited by blending the crude extract at a ratio of about 0.1 to 10%. The skin external preparation composition of the present invention can be applied to cosmetics such as creams, milky lotions, lotions, cleansers, pack-soaps, ointments, paste preparations, lotions, tinctures, liniments, etc. in accordance with the actual use. It can be made into a dosage form similar to a topical drug such as a jelly or an aerosol. Other ingredients may be any commonly used ingredients, and other medicinal agents may also be used in combination. Next, the present invention will be explained in more detail with reference to reference examples and examples. Reference example 1 Commercially available Termilla chebura R
etzius) fruit powder 1 kq to methanol-IV2
! After stirring for 1 hour at room temperature, the extract was filtered. This operation is repeated three times, and the entire extract is concentrated to dryness under reduced pressure at 60° C. or lower to obtain a crude extract. This extract was dissolved in 1j of water, cooled to 10°C, and an aqueous IN sodium hydroxide solution was added with stirring.
Adjust to. Continuous extraction with ethyl acetate under reduced pressure for 4 days,
The solvent is distilled off from the extract under reduced pressure at a temperature below 40°C. The residue was dissolved in 0.61 g of water, extracted continuously with ethyl ether for 12 hours, and then, after removing the ether, the aqueous layer was extracted under reduced pressure.
Concentrate to dryness at 60°C or below to obtain 70 g of a refined extract containing a large amount of tannins. 10 g of this extract was subjected to droplet countercurrent partition chromatography, and ethyl acetate/I/-n-propano--water (4:2
Develop using the ascending method with a mixture of 1 and 2. Collect fractions between 0.4 and 0.71. %40°C under reduced pressure
Concentrate as follows, dissolve the concentrate in ethanol, add water, and collect the precipitate in a furnace to obtain 0.1 g of Terkevin in the form of a light brown powder. Reference Example 2 1 kg of dried Kennoshoko powder leaves was mixed with methanol-water (1 kg).
:1) Mixed liquid 5! Homogenize with a mixer for 1 hour and divide the extract. Repeat this operation 3 times. The entire extract was concentrated to dryness at below 60°C, and the crude extract 25
Obtain 0g. 200 g of this extract is dissolved in 1/2 of water, ethyl ether N11 is added thereto, shaken well, and the ethyl ether layer is removed. After repeating this operation three times, 10.81 tL of ethyl acetate is added to the remaining aqueous layer, shaken well, and extracted. After repeating this operation 10 times, combine the extracts and
Concentrate to dryness under reduced pressure at below 0°C to obtain 5.5 g of purified extract. 3 g of this extract was subjected to droplet countercurrent partition chromatography using chloroform-methanol-water (45:50:2.
1) Develop by descending method using the mixed solution. 0.31~0
.. 41 fractions were collected under reduced pressure. Concentrate at 40°C and collect the precipitate separated from the water. Add 0.2 g of yellow powdered geraniin. Reference example 3: 1 kg of fresh leaves of Akamegashiwa with water and acetone

【3ニア
】混液5!を加え、参考例2と同様に抽出する。得られ
た抽出液を1jに濃縮し、これにエチルエーテル1jを
加え、参考例2と同様に処理して精製抽出物40gを得
る。 この抽出物10gを液滴向流分配クロマトグラフィーに
付し−n−ブタノールー酢酸−水(4:l:5)混液を
用い上昇法で展開する。4〜5jの画分を捕集し、fi
正圧下60°C以下で濃縮乾固し、残漬に酢酸エチルを
加えて溶解する。これに。 石油ベンジンを加え、生じた沈澱を併収し、淡黄色粉末
状のマロツシン酸0.14gを得る。 参考例4 市販地楡(Sangnisorba efficiru
lis L、var。 carnea、 Reg、 ) (D乾燥根1 #e前
記参考例ト同様にして水−アセトン(1:1)混g!3
/で抽出し。 同様に操作して精製抽出物を得る。 この抽出物50gをエタノ−/l/200−に溶解し、
セファデックスLH−20のゲルクロマトグラフィー(
湿容量1.57)に付し、エタノール101で溶出する
。ついで、70%アセトンで溶出し−その21の画分を
捕集し一減圧下−40’Cで濃縮乾固して地楡総タンニ
ン10gを得る。 地楡総タンニン5gをセファデックスLH,20のゲル
クロマトグラフィー(湿容量150m/)に付し、エタ
ノール−水(7:3)混HAlで溶出後、エタノール−
水−アセトン(65:80:5)で溶出し、その画分0
.2/i捕集する。この溶出液を減圧下、40°Cで濃
縮乾固し、淡褐色の地楡タンニンA 0.5 gを得る
。 実施例1 常法により、つぎの処方に従って、参考例1で得られた
テルケビンを配合した5日やけ、雪やけ後のほてりをし
ずめる乳液を製造した。 成分        % ステアリン酸               2.0セ
タノー)V                 Q・5
ラノリン                 2.0イ
ソプロピルミリステート         2,0スク
ワレン               3.0流動パラ
フイン              8.0ポリオキシ
エチレンセチルエーテ/L’     1.7ソルビタ
ンモノステアレート        0.8テルケビン
               1.0トリエタノール
アミン           1.0グリセリン   
          4.0香料および防腐剤    
        適量水              
100%に調整実施例2 常法により一つぎの処方に従って、参考例3で得られた
アカメガシワ精製抽出物および参考例4で得られた地楡
総タンニンを配合したサンタンローションを製造した。 成分        % カルボキシポリメチレン(力(シル940)    1
.5ポリエチレングリコ−/L/600      5
.0ジヒドロキシアセトン           1.
0ジイソプロパツールアミン        適量香料
                  適量アカメガシ
ワ精製抽出物         0.5地楡総タンニン
             0.5水        
      100%に調整このローションを18〜2
2才の女子10名が海水浴の際背中に塗布して効果を検
討した結果。 全員とも皮膚刺激、炎症反応は認められなかった。 また日やけ後、実施例1の乳液を腕に塗布して効果を検
討した結果、皮膚刺激、炎症反応は認められなかった。 実施例3 常法により、つぎの処方に従って、参考例3で得られた
マロツシン酸を配合した肌あれ用のクリームを製造した
。 成分        % ミツロウ                10.0パ
ラフインワツクス           6.0ラノリ
ン                 3.0イソ7”
ロピルミリスf  )           6.0ス
クワレン               8.0流動パ
ラフイン            25.0ポリオキシ
エチレンソルビタンモノステアレート       1
.8ソ7レビタンモノヌテアレート        4
.2マロツシン酸              0・2
防腐剤                適量プロピレ
ングリコール          2・0尿素    
              2.0水       
        100%に調整実施例4 常法により、つぎの処方に従って、アフターンエープロ
ーションe製造した。 成分        % エチルアルコ−/L’               
55.0ジプロピレングリコール          
1.0ホリオキシエチレン硬化ヒマシ油0.5オオバヤ
シャブシ、ゲンノショウコ混合抽出物     0.5
香料                  0・5水 
              100%に調整実施例5 常法により、つぎの処方に従って、熱傷−外傷治療用軟
膏を製造した。 成分                 のポリエチレ
ングリコ−/I/400     53.8ポリエチレ
ングリコール1500    19.0ポリエチレング
リコール4000    21.0カルボポール9B4
            1.0阿子精製抽出物   
          5.0アクリノー)Li微末  
          0.2この軟骨を1局所に1〜2
度の熱傷を受けた患者9名の熱傷部位に塗布した結果、
9名中8名は水泡、痛みが認められず著効であった。、
1名は痛みが感じられたが水泡は認められず有効であっ
た。 実施例6 常法により、つぎの処方に従って、亜鉛華す二メントを
得、湿疹、虫刺傷、掻痒性皮膚疾患に効果のあるリニメ
ントを製造した。 成分        % 液状フェノ−/l/                
2.2トラガント                 
5.0グリセリン             3.0酸
化亜鉛微末             10.0アルヌ
シイン                 1.0水 
              100%に調整実施例7 常法により、つぎの処方に従い、参考例4で得られた地
検タンニンAを配合した熱傷治療用エアゾルを製造した
。 成分        % メントー/l/                  
 0.1クロロブタノ−/L’           
   0.3ヘキサクロロフエン          
 0,3地楡タンニンA2.0 ジプロピレングリコール        19.1イソ
プロパツール           13.2噴射剤 
              65.0特許出願人サン
スター株式会社?υ)1名代 埋入 弁理士 青 山 
 葆ほか2名手、続補正書(帥) 昭和56年11月20日 特許庁長官  殿 1事件の表示 昭和56年特許願第 135771   号2発明の名
称 タンニン配合皮膚外用剤組成物 3補正をする者 事件との関係 特許出願人 、住所 大阪府高槻市朝日町3番1号 名称サンスター株式会社 (ほか1名) 4、代理人 住所 大阪府大阪市東区本町2−10 本町ビル内氏名
 弁理士(6214)青 山 葆 ほか 2名7、補正
の内容 (1)明M書第15頁下がら7行目「展開するが、)l
i/−ルJとあるを「展開するが、クロロホルム−メタ
ノール」と補正スル。 (2)回書第18頁下がら7行目「ゲンノショウコ末乾
燥葉」とあるを「ゲンノショウコ未乾燥葉」と補正する
。 以上
[3 Near] Mixed liquid 5! and extracted in the same manner as in Reference Example 2. The obtained extract was concentrated to 1j, to which was added ethyl ether 1j, and treated in the same manner as in Reference Example 2 to obtain 40 g of purified extract. 10 g of this extract was subjected to droplet countercurrent partition chromatography and developed using a mixture of n-butanol-acetic acid-water (4:1:5) in an ascending manner. Collect fractions 4 to 5j, fi
Concentrate to dryness under positive pressure at 60°C or lower, and add ethyl acetate to the residue to dissolve. to this. Petroleum benzine is added and the resulting precipitate is collected to obtain 0.14 g of malotsic acid in the form of pale yellow powder. Reference example 4 Commercially available elm (Sangnisorba efficiru)
lis L, var. carnea, Reg, ) (D dried root 1 #e Mix water-acetone (1:1) in the same manner as in the above reference example G! 3
Extract with /. A purified extract is obtained in the same manner. Dissolve 50g of this extract in ethanol/l/200-
Sephadex LH-20 gel chromatography (
Wet volume 1.57) and elute with ethanol 101. Then, it was eluted with 70% acetone and the 21 fractions were collected and concentrated to dryness under reduced pressure at -40'C to obtain 10 g of total tannin. 5 g of total tannin was subjected to Sephadex LH, 20 gel chromatography (wet volume 150 m/), and after elution with ethanol-water (7:3) mixed HAl, ethanol-
Elute with water-acetone (65:80:5), the fraction 0
.. Collect 2/i. This eluate was concentrated to dryness at 40°C under reduced pressure to obtain 0.5 g of light brown elm tannin A. Example 1 A milky lotion containing Terkevin obtained in Reference Example 1 to relieve hot flashes after sunburn and snowburn was produced by a conventional method according to the following formulation. Ingredients % Stearic acid 2.0 cetanol) V Q・5
Lanolin 2.0 Isopropyl myristate 2.0 Squalene 3.0 Liquid paraffin 8.0 Polyoxyethylene cetyl ether/L' 1.7 Sorbitan monostearate 0.8 Terkevin 1.0 Triethanolamine 1.0 Glycerin
4.0 Fragrances and Preservatives
appropriate amount of water
Adjustment to 100% Example 2 A suntan lotion was prepared by blending the purified extract of red mulberry wrinkle obtained in Reference Example 3 and the red mulberry total tannin obtained in reference example 4 according to the following recipe using a conventional method. Ingredients % Carboxypolymethylene (Sil 940) 1
.. 5 Polyethylene glycol/L/600 5
.. 0 dihydroxyacetone 1.
0 Diisopropaturamine (appropriate amount) Fragrance (appropriate amount) Purified extract of Akamega wrinkles 0.5 Diisopropaturamine total tannins 0.5 Water
Adjust this lotion to 100% 18-2
The results were investigated by 10 2-year-old girls who applied the product to their backs while bathing in the sea. No skin irritation or inflammatory reaction was observed in any of the patients. Furthermore, after sunburn, the emulsion of Example 1 was applied to the arm to examine its effect, and as a result, no skin irritation or inflammatory reaction was observed. Example 3 A cream for rough skin containing the malotsic acid obtained in Reference Example 3 was produced by a conventional method according to the following formulation. Ingredients % Beeswax 10.0 Paraffin wax 6.0 Lanolin 3.0 Iso7”
Lopyrumiris f) 6.0 Squalene 8.0 Liquid paraffin 25.0 Polyoxyethylene sorbitan monostearate 1
.. 8 So 7 Levitan mononutearate 4
.. 2 Malotsic acid 0.2
Preservatives Appropriate amount of propylene glycol 2.0 urea
2.0 water
Adjustment to 100% Example 4 Afternap Lotion e was manufactured according to the following recipe using a conventional method. Ingredients % Ethyl alcohol/L'
55.0 dipropylene glycol
1.0 Horioxyethylene hydrogenated castor oil 0.5 Obayashishabushi and Gennoshoko mixed extract 0.5
Fragrance 0.5 water
Adjustment to 100% Example 5 An ointment for the treatment of burns and trauma was prepared according to the following formulation in a conventional manner. Ingredients Polyethylene glycol/I/400 53.8 Polyethylene glycol 1500 19.0 Polyethylene glycol 4000 21.0 Carbopol 9B4
1.0 Ako purified extract
5.0 Acryno) Li fine powder
0.2 Apply 1 to 2 pieces of this cartilage to one location.
As a result of applying it to the burn area of 9 patients who suffered from degree burns,
Eight of the nine patients had no blisters or pain, and the treatment was excellent. ,
One patient felt pain, but no blisters were observed and the treatment was effective. Example 6 A zinc oxide liniment was obtained by a conventional method according to the following recipe, and a liniment effective for treating eczema, insect bites, and pruritic skin diseases was produced. Ingredients % Liquid phenol/l/
2.2 Tragacanth
5.0 Glycerin 3.0 Zinc oxide fine powder 10.0 Alnuciin 1.0 Water
Adjustment to 100% Example 7 An aerosol for treating burns containing the District Examination Tannin A obtained in Reference Example 4 was produced according to the following recipe using a conventional method. Ingredients % Mentor/l/
0.1 chlorobutano/L'
0.3 hexachlorophene
0.3 Elm tannin A2.0 Dipropylene glycol 19.1 Isopropanol 13.2 Propellant
65.0 Patent applicant Sunstar Co., Ltd.? υ) 1 person Patent attorney Aoyama
2 other masters, continuation amendment (shu) November 20, 1980 Commissioner of the Japan Patent Office Tono 1 Indication of the case 1982 Patent Application No. 135771 2 Name of the invention Tannin-containing skin external preparation composition 3 Person making the amendment Relationship to the case Patent applicant, Address: 3-1 Asahi-cho, Takatsuki-shi, Osaka Name: Sunstar Co., Ltd. (and one other person) 4. Address: Inside Honmachi Building, 2-10 Honmachi, Higashi-ku, Osaka-shi, Osaka Name: Patent attorney ( 6214) Aoyama Ao et al. 7, Contents of the amendment (1) Mei M, page 15, bottom 7th line “I will expand, but)
I/-L J was corrected to ``Develop, but chloroform-methanol''. (2) In the 7th line from the bottom of page 18 of the circular, the phrase ``terminal dry leaves of gennoshouko'' has been corrected to ``undried leaves of gennoshouko.''that's all

Claims (4)

【特許請求の範囲】[Claims] (1)有効成分として、ヘキサヒドロキシジフェノイル
基およびデヒドロヘキサヒドロキンジフェノイル基から
なる群から選ばれる基を含むタンニンの1種または2種
似主を配合したことを特徴とする皮膚外用剤組成物。
(1) A skin external preparation characterized by containing as an active ingredient one or two tannins containing a group selected from the group consisting of hexahydroxydiphenoyl group and dehydrohexahydroquine diphenoyl group. Composition.
(2)該タンニンがエラジタソニンである前記第(1)
項の皮膚外用剤組成物。
(2) The above-mentioned (1), wherein the tannin is ellagitasonine.
A composition for external use on the skin.
(3)該タンニンが地楡タンニンである゛前記第(1)
項の皮膚外用剤組成物。
(3) The tannin is ground elm tannin (see (1) above)
A composition for external use on the skin.
(4)該タンニンを組成物全量に対して0.05〜5重
量%配合した前記第(1)項〜第(3)項いずれか1つ
の皮膚外用剤組成物。
(4) The skin external preparation composition according to any one of items (1) to (3) above, which contains the tannin in an amount of 0.05 to 5% by weight based on the total amount of the composition.
JP56135771A 1981-08-29 1981-08-29 Tannin-containing composition for skin for external application Pending JPS5838209A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56135771A JPS5838209A (en) 1981-08-29 1981-08-29 Tannin-containing composition for skin for external application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56135771A JPS5838209A (en) 1981-08-29 1981-08-29 Tannin-containing composition for skin for external application

Publications (1)

Publication Number Publication Date
JPS5838209A true JPS5838209A (en) 1983-03-05

Family

ID=15159469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56135771A Pending JPS5838209A (en) 1981-08-29 1981-08-29 Tannin-containing composition for skin for external application

Country Status (1)

Country Link
JP (1) JPS5838209A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124511A (en) * 1984-07-13 1986-02-03 Pola Chem Ind Inc Lip cosmetic
JPS61178908A (en) * 1984-02-27 1986-08-11 Kanebo Ltd Skin cosmetic
FR2618678A1 (en) * 1987-07-31 1989-02-03 Bensussan Emile Pharmaceutical composition for the treatment of inflammations of the buccal cavity
JPH01128934A (en) * 1987-11-12 1989-05-22 Shiseido Co Ltd Protease inhibitor
JPH01128933A (en) * 1987-11-12 1989-05-22 Shiseido Co Ltd Hyaluronidase inhibitor
US5073545A (en) * 1987-06-09 1991-12-17 Lion Corporation Agent containing an ellagic acid series compound for external application and use thereof
JPH0812586A (en) * 1994-07-01 1996-01-16 Mikimoto Pharmaceut Co Ltd Antiplasmin agent
EP0727217A3 (en) * 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical composition containing god-type ellagitannin as active ingredient
EP0727218A3 (en) * 1995-02-10 1997-01-15 Suntory Ltd Anti-allergic composition containing god-type ellagitannin as active ingredient
WO1999034808A1 (en) * 1998-01-09 1999-07-15 Laboratoires Dolisos Use of extracts of geraniine geranium or related compounds for preparing analgesic medicines of central non-morphine type
KR20000063597A (en) * 2000-07-25 2000-11-06 황성빈 Plasma Tonic Sin Hair
JP2000319159A (en) * 1999-05-10 2000-11-21 Nonogawa Shoji Kk Skin preparation for external use
WO2001019377A1 (en) * 1999-09-10 2001-03-22 Fytokem Products Inc. Oenothein medicaments
KR100361551B1 (en) * 1994-12-23 2003-01-29 주식회사 엘지씨아이 Cosmetic composition containing an extract of elm tree for preventing skin aging
JP2007277100A (en) * 2006-04-03 2007-10-25 Noevir Co Ltd Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor
KR100893166B1 (en) * 2002-03-18 2009-04-17 (주)케어젠 The application of the glycoprotein-concentrated fraction from Ulmus davidiana as a component of the cosmetics
CN113476465A (en) * 2021-07-09 2021-10-08 昆明医科大学 Application of geraniin in preparing medicine for treating burns and scalds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5677215A (en) * 1979-11-28 1981-06-25 Pola Chem Ind Inc Cosmetic for skin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5677215A (en) * 1979-11-28 1981-06-25 Pola Chem Ind Inc Cosmetic for skin

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61178908A (en) * 1984-02-27 1986-08-11 Kanebo Ltd Skin cosmetic
JPH0533203B2 (en) * 1984-02-27 1993-05-19 Kanebo Ltd
JPS6124511A (en) * 1984-07-13 1986-02-03 Pola Chem Ind Inc Lip cosmetic
US5073545A (en) * 1987-06-09 1991-12-17 Lion Corporation Agent containing an ellagic acid series compound for external application and use thereof
FR2618678A1 (en) * 1987-07-31 1989-02-03 Bensussan Emile Pharmaceutical composition for the treatment of inflammations of the buccal cavity
JPH01128934A (en) * 1987-11-12 1989-05-22 Shiseido Co Ltd Protease inhibitor
JPH01128933A (en) * 1987-11-12 1989-05-22 Shiseido Co Ltd Hyaluronidase inhibitor
JPH0812586A (en) * 1994-07-01 1996-01-16 Mikimoto Pharmaceut Co Ltd Antiplasmin agent
KR100361551B1 (en) * 1994-12-23 2003-01-29 주식회사 엘지씨아이 Cosmetic composition containing an extract of elm tree for preventing skin aging
EP0727218A3 (en) * 1995-02-10 1997-01-15 Suntory Ltd Anti-allergic composition containing god-type ellagitannin as active ingredient
EP0727217A3 (en) * 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical composition containing god-type ellagitannin as active ingredient
WO1999034808A1 (en) * 1998-01-09 1999-07-15 Laboratoires Dolisos Use of extracts of geraniine geranium or related compounds for preparing analgesic medicines of central non-morphine type
FR2773487A1 (en) * 1998-01-09 1999-07-16 Dolisos Lab USE OF AQUEOUS, HYDROALCOOLIC AND ACETONIC RAW EXTRACTS OF GERANIUMS, GERANIIN OR RELATED COMPOUNDS FOR THE PREPARATION OF NON-MORPHINIC CENTRAL TYPE ANALGESIC DRUGS
JP2000319159A (en) * 1999-05-10 2000-11-21 Nonogawa Shoji Kk Skin preparation for external use
WO2001019377A1 (en) * 1999-09-10 2001-03-22 Fytokem Products Inc. Oenothein medicaments
US6528490B2 (en) 1999-09-10 2003-03-04 Fytoken Products, Inc. Oenothein medicaments
KR20000063597A (en) * 2000-07-25 2000-11-06 황성빈 Plasma Tonic Sin Hair
KR100893166B1 (en) * 2002-03-18 2009-04-17 (주)케어젠 The application of the glycoprotein-concentrated fraction from Ulmus davidiana as a component of the cosmetics
JP2007277100A (en) * 2006-04-03 2007-10-25 Noevir Co Ltd Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor
CN113476465A (en) * 2021-07-09 2021-10-08 昆明医科大学 Application of geraniin in preparing medicine for treating burns and scalds

Similar Documents

Publication Publication Date Title
US5266318A (en) Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed
JPS5838209A (en) Tannin-containing composition for skin for external application
US6025334A (en) Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US8449924B2 (en) Process for the preparation of plant extracts for treating skin disorders and enhancing healing of wounds
KR101219520B1 (en) Anti-inflammatory, anti-oxidative or anti-bacterial compositions
EP0666750A1 (en) Mixtures or complexes containing calcium and sulfate
JPH10279491A (en) Interleukin 4 production inhibitor
KR20170053388A (en) Cosmetic composition comprising mixture extracts of curcuma longa Linn, apple, grape, having anti-pollution effect in skin cells and method manufacturing thereof
KR20100103479A (en) Cosmetic or dermatological composition containing an orchid extract, and cosmetic care method using said composition
JPS5916816A (en) Composition for external use
WO2004105689A2 (en) Topical composition for the treatment of skin disorders and methods of using the same
JPS5838208A (en) Tannin-containing composition for oral cavity
CN113925907B (en) Antibacterial, anti-inflammatory and antiallergic composition, and preparation method and application thereof
KR20040041912A (en) Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition
JPH04169535A (en) Composition for skin external preparation
JP3487617B2 (en) Cosmetics
CN112022761A (en) High-moisturizing whitening repair gel
JPH0812586A (en) Antiplasmin agent
JPH06293652A (en) Antiallergic comsmetic composition
JPS62234006A (en) External drug for skin
JPH0570349A (en) Antiplasmin agent
JP2003221333A (en) Agent for inhibiting hyaluronidase
JPH02240009A (en) Skin external application agent
JPS61254510A (en) External agent for skin
KR20070033133A (en) A composition for external preparation for the protection and the treatment of atopic dermatitis